Calithera Biosciences (CALA) Reports Q3 Loss of $0.49/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Calithera Biosciences (CALA) Files $150M Common Stock Shelf
November 10, 2015 9:41 AM ESTCalithera Biosciences (NASDAQ: CALA) filed a registration with the U.S. SEC to sell up to $150 million worth of common stock.
... MoreLeerink Partners Reiterates Outperform on Calithera Biosciences (CALA) Following 3Q
November 10, 2015 7:00 AM ESTLeerink Partners reiterated an Outperform rating and $13.00 price target on Calithera Biosciences (NASDAQ: CALA) following the company's 3Q earnings report. CALA reported 3Q15 EPS of ($0.49), slightly better than consensus estimates of ($0.54).
Analyst Paul Matteis commented, "After the close, CALA reported 3Q15 EPS of ($0.49), in-line with... More
